

**Food and microbiota metabolites associate with cognitive decline in older subjects:
A twelve-year prospective study**

Raúl González-Domínguez^{1,2*}, Pol Castellano-Escuder^{1,2,3}, Francisco Carmona^{2,3},
Sophie Lefèvre-Arbogast⁴, Dorrain Y. Low⁵, Andrea Du Preez⁶, Silvie R. Ruigrok⁷,
Claudine Manach⁵, Mireia Urpi-Sarda^{1,2}, Aniko Korosi⁷, Paul J. Lucassen⁷, Ludwig
Aigner⁸, Mercè Pallàs⁹, Sandrine Thuret⁶, Cécilia Samieri⁴, Alex Sánchez-Pla^{2,3},
Cristina Andres-Lacueva^{1,2*}

¹Biomarkers and Nutrimetabolomics Laboratory, Faculty of Pharmacy and Food Sciences, University of Barcelona, 08028 Barcelona, Spain. ²CIBER Fragilidad y Envejecimiento Saludable (CIBERfes), Instituto de Salud Carlos III, 28029 Madrid, Spain. ³Department of Genetics, Microbiology and Statistics, University of Barcelona, 08028 Barcelona, Spain. ⁴University of Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR 1219, F-33000 Bordeaux, France. ⁵Université Clermont Auvergne, INRAE, UNH, F-63000 Clermont Ferrand, France. ⁶Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 9NU, UK. ⁷Brain Plasticity Group, Swammerdam Institute for Life Sciences, Center for Neuroscience, University of Amsterdam, 1098 XH Amsterdam, The Netherlands. ⁸Institute of Molecular Regenerative Medicine, Spinal Cord Injury and Tissue Regeneration Center Salzburg, Paracelsus Medical University, Salzburg 5020, Austria. ⁹Pharmacology Section, Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy and Food Sciences, and Institut de Neurociències, University of Barcelona, 08028 Barcelona, Spain.

*Corresponding authors: Dr. Raúl González-Domínguez, Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. de Joan XXIII, 27-31, 08028 Barcelona (Spain), Tel. +34-934024513, E-mail: raul.gonzalez@ub.edu; Prof. Cristina Andres-Lacueva, Faculty of Pharmacy and Food Sciences, University of Barcelona, Av. de Joan XXIII, 27-31, 08028 Barcelona (Spain), Tel. +34-934034840, E-mail: candres@ub.edu

Table S1. Concentrations (expressed as mean \pm standard deviation, $\mu\text{g L}^{-1}$) detected within the cases and controls subjects for the metabolites identified to be associated with cognitive decline by LASSO regression in the discovery (Bordeaux) and validation (Dijon) sample sets.

| Metabolites | Bordeaux sample set | | Dijon sample set | |
|---|---------------------------|---------------------------|---------------------------|-----------------------------|
| | cases | controls | cases | controls |
| <i>Phenolic acids and derivatives</i> | | | | |
| Vanillin | 21.3 \pm 38.2 | 29.3 \pm 45.8 | 7.2 \pm 31.1 | 13.2 \pm 47.7 |
| 3-Hydroxybenzoic acid sulfate (3-HBA-S) | 8.2 \pm 13.6 | 8.6 \pm 12.1 | 14.5 \pm 19.0 | 16.1 \pm 18.0 |
| 2-Hydroxybenzoic acid (2-HBA) | 189.2 \pm 1508.2 | 100.5 \pm 405.6 | 162.1 \pm 1200.9 | 50.1 \pm 185.7 |
| 3,4-Dihydroxybenzoic acid (3,4-DHBA) | 40.8 \pm 93.9 | 45.3 \pm 65.2 | 32.4 \pm 103.6 | 23.6 \pm 26.8 |
| 3-Hydroxyphenylacetic acid sulfate (3-HPAA-S) | 52358.7 \pm 104446.7 | 52881.8 \pm 121984.6 | 60125.6 \pm 132259.5 | 23424.6 \pm 71751.2 |
| Dihydroferulic acid sulfate (DHFA-S) | 3.0 \pm 8.7 | 4.0 \pm 8.9 | 2.7 \pm 5.9 | 2.7 \pm 6.1 |
| 3-Hydroxyhippuric acid (3-HHA) | 49.1 \pm 58.5 | 50.9 \pm 66.4 | 33.8 \pm 41.4 | 42.2 \pm 50.5 |
| <i>Xanthine alkaloids</i> | | | | |
| 3-Methylxanthine | 51.0 \pm 140.8 | 75.5 \pm 168.1 | 80.6 \pm 173.0 | 65.4 \pm 113.3 |
| Caffeine | 1202.7 \pm 1403.1 | 888.0 \pm 1044.1 | 692.6 \pm 943.4 | 687.5 \pm 854.2 |
| 1,3-Dimethyluric acid | 46.9 \pm 34.7 | 40.5 \pm 29.8 | 34.9 \pm 38.2 | 40.7 \pm 33.5 |
| <i>Artificial sweeteners</i> | | | | |
| Saccharin | 11.5 \pm 35.4 | 6.8 \pm 26.4 | 5.9 \pm 25.2 | 3.6 \pm 13.8 |
| Acesulfame K | 7.6 \pm 35.3 | 5.2 \pm 24.5 | 2.8 \pm 9.3 | 5.6 \pm |

| | | | | |
|---|---------------------|---------------------|----------------------|---------------------|
| | | | | 29.2 |
| <i>Other food-related metabolites</i> | | | | |
| Umbelliferone sulfate | 1.7 ± 1.6 | 3.4 ± 13.9 | 1.3 ± 2.2 | 1.6 ± 3.7 |
| 2-Furoylglycine | 9.6 ± 30.0 | 11.4 ± 41.4 | 6.8 ± 20.2 | 5.0 ± 9.5 |
| Tartaric acid | 111.4 ± 140.6 | 97.1 ± 134.4 | 101.5 ± 193.5 | 74.7 ± 142.2 |
| Proline betaine | 278.3 ± 256.5 | 220.2 ± 222.0 | 277.6 ± 292.7 | 315.8 ± 275.2 |
| Enterolactone sulfate | 1.1 ± 1.6 | 1.4 ± 1.7 | 0.2 ± 1.0 | 0.1 ± 0.5 |
| 5-(4'-Hydroxy-3'-methoxyphenyl)- γ -valerolactone sulfate (MHPV-S) | 21.4 ± 55.5 | 34.2 ± 74.5 | 35.0 ± 101.3 | 19.0 ± 55.6 |
| Ergothioneine | 1268.3 ± 1637.0 | 1308.8 ± 1807.0 | 272.3 ± 290.7 | 381.7 ± 398.5 |
| Ethyl sulfate | 15.8 ± 44.6 | 13.8 ± 44.1 | 7.6 ± 19.9 | 4.6 ± 14.9 |
| cis-Resveratrol 3-sulfate | 6.8 ± 8.2 | 5.7 ± 6.4 | 20.6 ± 30.4 | 22.3 ± 34.3 |
| <i>Aromatic amino acid derivatives</i> | | | | |
| Indoxyl sulfate | 1205.8 ± 809.7 | 1291.9 ± 690.6 | 745.1 ± 410.3 | 706.1 ± 388.9 |
| 4-Hydroxyphenylacetic acid glucuronide (4-HPAA-G) | 82.8 ± 281.2 | 46.9 ± 180.5 | 76.0 ± 324.2 | 21.3 ± 114.8 |
| 3,4-Dihydroxyphenylacetic acid sulfate (DOPAC-S) | 9019.7 ± 21384.7 | 9205.1 ± 26811.2 | 12516.7 ± 29668.5 | 5275.2 ± 11550.2 |
| 4-Hydroxyphenyllactic acid sulfate (4-HPLA-S) | 452.1 ± 1055.8 | 440.1 ± 1239.4 | 499.6 ± 1305.7 | 212.2 ± 629.3 |
| 5-Hydroxytryptophan | 93.0 ± 48.9 | 93.4 ± 43.4 | 154.2 ± 115.2 | 204.0 ± 181.2 |
| 4-Methylcatechol sulfate (4-MeCAT-S) | 3906.2 ± 4286.8 | 5058.7 ± 8976.6 | 4963.8 ± 7482.6 | 3888.8 ± 4501.6 |
| Phenylacetylglutamine | 1025.6 ± 726.6 | 857.4 ± 536.8 | 1050.2 ± 611.4 | 951.3 ± 647.0 |

| | | | | |
|--|----------------------|----------------------|---------------------|---------------------|
| p-Cresol sulfate | 4395.1 ± 1980.6 | 4224.9 ± 1894.8 | 3773.7 ± 1883.7 | 3282.5 ± 1815.3 |
| Serotonin | 77.0 ± 29.9 | 76.5 ± 27.0 | 47.0 ± 38.5 | 54.8 ± 41.9 |
| <i>Fatty acids and derivatives</i> | | | | |
| Myristic acid | 17318.1 ± 11356.4 | 15060.6 ± 10631.2 | 20858.1 ± 7616.1 | 18396.0 ± 5991.8 |
| Lauric acid | 2989.4 ± 2704.4 | 2592.3 ± 2172.4 | 11949.8 ± 7133.1 | 10055.2 ± 5493.6 |
| Linoleoyl-carnitine | 89.1 ± 39.5 | 76.0 ± 34.1 | 53.8 ± 5.5 | 54.6 ± 10.9 |
| <i>Other endogenous metabolites</i> | | | | |
| Betaine | 25364.7 ± 11863.7 | 29467.6 ± 12956.8 | 8044.8 ± 4121.9 | 8149.0 ± 3630.6 |
| Dehydroepiandrosterone sulfate (DHEAS) | 593.8 ± 502.3 | 666.3 ± 527.8 | 370.8 ± 309.1 | 356.1 ± 292.0 |
| Citric acid | 5608.7 ± 5315.1 | 6596.5 ± 6718.9 | 3800.3 ± 3739.1 | 3970.9 ± 3324.0 |
| Thiamine | 26.2 ± 37.5 | 26.2 ± 28.7 | 6.9 ± 19.5 | 7.7 ± 16.6 |

Table S2. Metabolites associated with subsequent cognitive decline in the total sample (i.e., combination of the populations from Bordeaux and Dijon) identified by least absolute shrinkage and selection operator (LASSO) penalized conditional logistic regression.

| Metabolites | Odds ratio |
|---|------------|
| <i>Phenolic acids and derivatives</i> | |
| 3-Hydroxybenzoic acid sulfate (3-HBA-S) | 0.87 |

| | |
|---|------|
| Hippuric acid (HA) | 0.98 |
| Vanillin | 0.83 |
| <i>Xanthine alkaloids</i> | |
| 3-Methylxanthine | 0.86 |
| 1-Methylxanthine | 0.96 |
| <i>Artificial sweeteners</i> | |
| Saccharin | 1.26 |
| <i>Other food-related metabolites</i> | |
| Umbelliferone sulfate | 0.91 |
| Ergothioneine | 0.90 |
| <i>Aromatic amino acid derivatives</i> | |
| Phenylacetylglutamine | 1.23 |
| p-Cresol glucuronide | 1.19 |
| 5-Hydroxytryptophan | 0.89 |
| 5-Hydroxyindoleacetic acid | 1.10 |
| 4-Hydroxyphenyllactic acid sulfate (4-HPLA-S) | 1.12 |
| <i>Fatty acids and derivatives</i> | |
| Oleic acid | 1.12 |
| Linoleic acid | 1.19 |
| Lauroyl-carnitine | 1.18 |
| Oleoyl-carnitine | 1.18 |
| <i>Other endogenous metabolites</i> | |
| Alanine | 1.09 |
| Glutamic acid | 1.14 |
| Carnosine | 1.22 |
| Creatinine | 1.00 |
| Guanosine | 1.06 |
| Riboflavin | 1.02 |
| Pantothenic acid | 1.13 |




Figure S1. Pearson's correlation analysis between the metabolites that were identified by bootstrap-enhanced least absolute shrinkage and selection operator (LASSO) penalized conditional logistic regression to be associated with subsequent cognitive decline in the discovery (Bordeaux, A) and validation (Dijon, B) sample sets.

AUC = 0.61, Sensitivity = 0.593, Specificity = 0.598




Figure S2. Receiver operating characteristic curve evaluating the performance of the 24-metabolite set identified in the discovery phase to predict the odds of CD in the external validation set.